Skip to main content
ASND
NASDAQ Life Sciences

Ascendis Pharma to Directly List Ordinary Shares on Nasdaq, Mandating ADS Exchange

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Neutral
Importance info
7
Price
$233.95
Mkt Cap
$13.533B
52W Low
$124.06
52W High
$248.6
52W Position info
89% above low
Off High info
5.9% below high
Rel. Volume info
1.1× avg
Market data snapshot near publication time

ASND sits 89% above its 52-week low of $124.06.

Summary

Ascendis Pharma announced plans to directly list its ordinary shares on The Nasdaq Global Select Market, effective April 20, 2026, requiring a mandatory exchange of all outstanding American Depositary Shares (ADSs) for ordinary shares.


Key Events · Corporate Governance and Compliance · ASND

  • Direct Nasdaq Listing

    Ascendis Pharma plans to list its ordinary shares directly on The Nasdaq Global Select Market, effective April 20, 2026.

  • Mandatory ADS Exchange

    All outstanding American Depositary Shares (ADSs) will be mandatorily exchanged for one ordinary share each.

  • Trading Transition

    The last day of ADS trading on Nasdaq is expected to be April 17, 2026, with ordinary shares commencing trading on April 20, 2026, under the ticker ASND.


Analysis · ASND · Life Sciences

This strategic move simplifies Ascendis Pharma's capital structure for U.S. investors by eliminating the American Depositary Share (ADS) program. The direct listing of ordinary shares on Nasdaq is anticipated to enhance liquidity, reduce administrative complexities and fees associated with ADSs, and potentially broaden the company's investor base. Investors currently holding ADSs will automatically receive ordinary shares, which will continue to trade under the existing ticker symbol ASND.

How filings like this one have moved

In the 30 days to Oct 16, 2026, 29.5% of the 1476 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.41%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, ASND was trading at $233.95 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $13.5B. The 52-week trading range was $124.06 to $248.60. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

ASND - Latest Insights

ASND
Oct 16, 2026, 7:45 AM EDT
Source: Dow Jones Newswires
Importance Score:
8
Price at Filing: $226.62
Real-time Price: $225.25 info
Change: -$1.37 (-0.60%) info
Market Cap: $14.05B info
ASND
Sep 14, 2026, 6:34 PM EDT
Source: Dow Jones Newswires
Importance Score:
8
Price at Filing: $267.00
Real-time Price: $225.25 info
Change: -$41.75 (-16%) info
Market Cap: $14.05B info
ASND
Sep 14, 2026, 6:30 PM EDT
Filing Type: 6-K
Importance Score:
7
Price at Filing: $263.15
Real-time Price: $225.25 info
Change: -$37.90 (-14%) info
Market Cap: $14.05B info
ASND
Sep 10, 2026, 9:52 AM EDT
Source: Benzinga
Importance Score:
8
Price at Filing: $262.10
Real-time Price: $225.25 info
Change: -$36.85 (-14%) info
Market Cap: $14.05B info
ASND
Sep 09, 2026, 5:21 PM EDT
Filing Type: 6-K
Importance Score:
8
Price at Filing: $260.81
Real-time Price: $225.25 info
Change: -$35.56 (-14%) info
Market Cap: $14.05B info